The Role of Peroxisome Proliferator-Activated Receptors in Pulmonary Vascular Disease

Nisbet, Rachel E.; Sutliff, Roy L.; Hart, C. Michael

doi:https://doi.org/10.1155/2007/18797

PPAR Research

On this page

Abstract References Copyright Related Articles

Special Issue

PPARs in Lung Biology and Disease

View this Special Issue

Review Article | Open Access

Volume 2007 | Article ID 018797 | https://doi.org/10.1155/2007/18797

The Role of Peroxisome Proliferator-Activated Receptors in Pulmonary Vascular Disease

Rachel E. Nisbet,¹Roy L. Sutliff,¹and C. Michael Hart¹

Academic Editor: Jesse Roman

Received01 Jan 2007

Accepted30 Apr 2007

Published26 Jun 2007

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily that regulate diverse physiological processes ranging from lipogenesis to inflammation. Recent evidence has established potential roles of PPARs in both systemic and pulmonary vascular disease and function. Existing treatment strategies for pulmonary hypertension, the most common manifestation of pulmonary vascular disease, are limited by an incomplete understanding of the underlying disease pathogenesis and lack of efficacy indicating an urgent need for new approaches to treat this disorder. Derangements in pulmonary endothelial-derived mediators and endothelial dysfunction have been shown to play a pivotal role in pulmonary hypertension pathogenesis. Therefore, the following review will focus on selected mediators implicated in pulmonary vascular dysfunction and evidence that PPARs, in particular PPARγ, participate in their regulation and may provide a potential novel therapeutic target for the treatment of pulmonary hypertension.

References

I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
View at: Publisher Site | Google Scholar
A. J. Gilde, K. A. J. M. van der Lee, P. H. M. Willemsen et al., “Peroxisome proliferator-activated receptor (PPAR) $a$ and PPAR $ß / d$ , but not PPAR $?$ , modulate the expression of genes involved in cardiac lipid metabolism,” Circulation Research, vol. 92, no. 5, pp. 518–524, 2003.
View at: Publisher Site | Google Scholar
I. Saluja, J. G. Granneman, and R. P. Skoff, “PPAR $δ$ agonists stimulate oligodendrocyte differentiation in tissue culture,” GLIA, vol. 33, no. 3, pp. 191–204, 2001.
View at: Publisher Site | Google Scholar
Y. Barak, D. Liao, W. He et al., “Effects of peroxisome proliferator-activated receptor $d$ on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002.
View at: Publisher Site | Google Scholar
N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes,” Journal of Steroid Biochemistry and Molecular Biology, vol. 93, no. 2–5, pp. 99–105, 2005.
View at: Publisher Site | Google Scholar
C.-H. Lee, A. Chawla, N. Urbiztondo et al., “Transcriptional repression of atherogenic inflammation: modulation by PPAR $δ$ ,” Science, vol. 302, no. 5644, pp. 453–457, 2003.
View at: Publisher Site | Google Scholar
G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors $a$ and $?$ induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.
View at: Publisher Site | Google Scholar
R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002.
View at: Publisher Site | Google Scholar
V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, “PPAR- $γ$ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer,” Neoplasia, vol. 7, no. 3, pp. 294–301, 2005.
View at: Publisher Site | Google Scholar
V. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator-activated receptor- $?$ activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004.
View at: Publisher Site | Google Scholar
K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J.-A. Gustafsson, “Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993.
View at: Publisher Site | Google Scholar
E. D. Rosen and B. M. Spiegelman, “PPAR $γ$ : a nuclear regulator of metabolism, differentiation, and cell growth,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001.
View at: Google Scholar
H. E. Xu, T. B. Stanley, V. G. Montana et al., “Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR $a$ ,” Nature, vol. 415, no. 6873, pp. 813–817, 2002.
View at: Google Scholar
F. Y. Ali, S. J. Davidson, L. A. Moraes et al., “Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR $ß$ ,” The FASEB Journal, vol. 20, no. 2, pp. 326–328, 2006.
View at: Publisher Site | Google Scholar
F. Y. Ali, K. Egan, G. A. FitzGerald et al., “Role of prostacyclin versus peroxisome proliferator-activated receptor $ß$ receptors in prostacyclin sensing by lung fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 242–246, 2006.
View at: Publisher Site | Google Scholar
P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPAR $γ$ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998.
View at: Publisher Site | Google Scholar
H. S. Camp, O. Li, S. C. Wise et al., “Differential activation of peroxisome proliferator-activated receptor- $?$ by troglitazone and rosiglitazone,” Diabetes, vol. 49, no. 4, pp. 539–547, 2000.
View at: Publisher Site | Google Scholar
Y. Kodera, K.-I. Takeyama, A. Murayama, M. Suzawa, Y. Masuhiro, and S. Kato, “Ligand type-specific interactions of peroxisome proliferator-activated receptor $γ$ with transcriptional coactivators,” Journal of Biological Chemistry, vol. 275, no. 43, pp. 33201–33204, 2000.
View at: Publisher Site | Google Scholar
J. M. Olefsky, “Treatment of insulin resistance with peroxisome proliferator-activated receptor $γ$ agonists,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 467–472, 2000.
View at: Google Scholar
M. A. Haidara, H. Z. Yassin, M. Rateb, H. Ammar, and M. A. Zorkani, “Role of oxidative stress in development of cardiovascular complications in diabetes mellitus,” Current Vascular Pharmacology, vol. 4, no. 3, pp. 215–227, 2006.
View at: Publisher Site | Google Scholar
R. E. Schmieder, “Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?” Journal of Hypertension, vol. 24, 2, pp. S31–S35, 2006.
View at: Publisher Site | Google Scholar
R. Budhiraja, R. M. Tuder, and P. M. Hassoun, “Endothelial dysfunction in pulmonary hypertension,” Circulation, vol. 109, no. 2, pp. 159–165, 2004.
View at: Publisher Site | Google Scholar
A. Hyduk, J. B. Croft, C. Ayala, K. Zheng, Z. J. Zheng, and G. A. Mensah, “Pulmonary hypertension surveillance—United States, 1980–2002,” Morbidity and Mortality Weekly Report, vol. 54, no. 5, pp. 1–28, 2005.
View at: Google Scholar
L. Du, C. C. Sullivan, D. Chu et al., “Signaling molecules in nonfamilial pulmonary hypertension,” The New England Journal of Medicine, vol. 348, no. 6, pp. 500–509, 2003.
View at: Publisher Site | Google Scholar
J. H. Newman, L. Wheeler, K. B. Lane et al., “Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred,” The New England Journal of Medicine, vol. 345, no. 5, pp. 319–324, 2001.
View at: Publisher Site | Google Scholar
U. C. Garg and A. Hassid, “Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells,” Journal of Clinical Investigation, vol. 83, no. 5, pp. 1774–1777, 1989.
View at: Google Scholar
H. Azuma, M. Ishikawa, and S. Sekizaki, “Endothelium-dependent inhibition of platelet aggregation,” British Journal of Pharmacology, vol. 88, no. 2, pp. 411–415, 1986.
View at: Google Scholar
A. P. L. Smith, E. A. G. Demoncheaux, and T. W. Higenbottam, “Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells,” Nitric Oxide, vol. 6, no. 2, pp. 153–159, 2002.
View at: Publisher Site | Google Scholar
M. A. Perrella, E. S. Edell, M. J. Krowka, D. A. Cortese, and J. C. Burnett Jr., “Endothelium-derived relaxing factor in pulmonary and renal circulations during hypoxia,” American Journal of Physiology, vol. 263, no. 1, part 2, pp. R45–R50, 1992.
View at: Google Scholar
F. Ichinose, R. Ullrich, A. Sapirstein et al., “Cytosolic phospholipase $A_{2}$ in hypoxic pulmonary vasoconstriction,” Journal of Clinical Investigation, vol. 109, no. 11, pp. 1493–1500, 2002.
View at: Publisher Site | Google Scholar
J. Wang, M. Juhaszova, L. J. Rubin, and X.-J. Yuan, “Hypoxia inhibits gene expression of voltage-gated $K^{+}$ channel $α$ subunits in pulmonary artery smooth muscle cells,” Journal of Clinical Investigation, vol. 100, no. 9, pp. 2347–2353, 1997.
View at: Google Scholar
S. Adnot, B. Raffestin, S. Eddahibi, P. Braquet, and P.-E. Chabrier, “Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia,” Journal of Clinical Investigation, vol. 87, no. 1, pp. 155–162, 1991.
View at: Google Scholar
R. H. Steinhorn, J. A. Russell, S. Lakshminrusimha, S. F. Gugino, S. M. Black, and J. R. Fineman, “Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension,” American Journal of Physiology, vol. 280, no. 1, pp. H311–H317, 2001.
View at: Google Scholar
R. M. Tuder, C. D. Cool, M. W. Geraci et al., “Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 6, pp. 1925–1932, 1999.
View at: Google Scholar
L. P. McQuillan, G. K. Leung, P. A. Marsden, S. K. Kostyk, and S. Kourembanas, “Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms,” American Journal of Physiology, vol. 267, no. 5, part 2, pp. H1921–H1927, 1994.
View at: Google Scholar
A. Giaid and D. Saleh, “Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension,” The New England Journal of Medicine, vol. 333, no. 4, pp. 214–221, 1995.
View at: Publisher Site | Google Scholar
C. Xue and R. A. Johns, “Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension,” The New England Journal of Medicine, vol. 333, no. 24, pp. 1642–1644, 1995.
View at: Publisher Site | Google Scholar
J. P. Khoo, L. Zhao, N. J. Alp et al., “Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension,” Circulation, vol. 111, no. 16, pp. 2126–2133, 2005.
View at: Publisher Site | Google Scholar
M. Nandi, A. Miller, R. Stidwill et al., “Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse,” Circulation, vol. 111, no. 16, pp. 2086–2090, 2005.
View at: Publisher Site | Google Scholar
P. Rosenkranz-Weiss, W. C. Sessa, S. Milstien, S. Kaufman, C. A. Watson, and J. S. Pober, “Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity,” Journal of Clinical Investigation, vol. 93, no. 5, pp. 2236–2243, 1994.
View at: Google Scholar
S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, “Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation,” Nature, vol. 399, no. 6736, pp. 601–605, 1999.
View at: Publisher Site | Google Scholar
D. Fulton, J.-P. Gratton, T. J. McCabe et al., “Regulation of endothelium-derived nitric oxide production by the protein kinase Akt,” Nature, vol. 399, no. 6736, pp. 597–601, 1999.
View at: Publisher Site | Google Scholar
T. Murata, M. Hori, K. Sakamoto, H. Karaki, and H. Ozaki, “Dexamethasone blocks hypoxia-induced endothelial dysfunction in organ-cultured pulmonary arteries,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 6, pp. 647–655, 2004.
View at: Publisher Site | Google Scholar
G. G. Konduri, J. Ou, Y. Shi, and K. A. Pritchard Jr., “Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension,” American Journal of Physiology, vol. 285, no. 1, pp. H204–H211, 2003.
View at: Google Scholar
G. García-Cardeña, R. Fan, V. Shah et al., “Dynamic activation of endothelial nitric oxide synthase by Hsp90,” Nature, vol. 392, no. 6678, pp. 821–824, 1998.
View at: Publisher Site | Google Scholar
T. Murata, K. Sato, M. Hori, H. Ozaki, and H. Karaki, “Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension,” Journal of Biological Chemistry, vol. 277, no. 46, pp. 44085–44092, 2002.
View at: Publisher Site | Google Scholar
S. Muzaffar, N. Shukla, G. D. Angelini, and J. Y. Jeremy, “Acute hypoxia simultaneously induces the expression of ${gp91}^{p h o x}$ and endothelial nitric oxide synthase in the porcine pulmonary artery,” Thorax, vol. 60, no. 4, pp. 305–313, 2005.
View at: Publisher Site | Google Scholar
K. A. Pritchard Jr., A. W. Ackerman, E. R. Gross et al., “Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 17621–17624, 2001.
View at: Publisher Site | Google Scholar
J. S. Beckman and W. H. Koppenol, “Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly,” American Journal of Physiology, vol. 271, no. 5, part 1, pp. C1424–C1437, 1996.
View at: Google Scholar
N. Kuzkaya, N. Weissmann, D. G. Harrison, and S. Dikalov, “Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase,” Journal of Biological Chemistry, vol. 278, no. 25, pp. 22546–22554, 2003.
View at: Publisher Site | Google Scholar
U. Landmesser, S. Dikalov, S. R. Price et al., “Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension,” Journal of Clinical Investigation, vol. 111, no. 8, pp. 1201–1209, 2003.
View at: Publisher Site | Google Scholar
S. Mehta, D. J. Stewart, D. Langleben, and R. D. Levy, “Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension,” Circulation, vol. 92, no. 6, pp. 1539–1545, 1995.
View at: Google Scholar
R. N. Channick, J. W. Newhart, F. W. Johnson et al., “Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests,” Chest, vol. 109, no. 6, pp. 1545–1549, 1996.
View at: Google Scholar
C. Marshall, A. J. Mamary, A. J. Verhoeven, and B. E. Marshall, “Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction,” American Journal of Respiratory Cell and Molecular Biology, vol. 15, no. 5, pp. 633–644, 1996.
View at: Google Scholar
N. Weissmann, S. Zeller, R. U. Schäfer et al., “Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 4, pp. 505–513, 2006.
View at: Publisher Site | Google Scholar
J. Q. Liu, I. N. Zelko, E. M. Erbynn, J. S. K. Sham, and R. J. Folz, “Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase ( ${gp91}^{p h o x}$ ),” American Journal of Physiology, vol. 290, no. 1, pp. L2–L10, 2006.
View at: Publisher Site | Google Scholar
J. Q. Liu, E. M. Erbynn, and R. J. Folz, “Chronic hypoxia-enhanced murine pulmonary vasoconstriction: role of superoxide and ${gp91}^{p h o x}$ ,” Chest, vol. 128, no. 6 supplement, pp. 594S–596S, 2005.
View at: Publisher Site | Google Scholar
J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart, “Peroxisome proliferator-activated receptor $γ$ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor $γ$ -dependent mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1810–1816, 2005.
View at: Publisher Site | Google Scholar
D. S. Calnek, L. J. Mazzella, S. Roser, J. Roman, and C. M. Hart, “Peroxisome proliferator-activated receptor $γ$ ligands increase release of nitric oxide from endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 52–57, 2003.
View at: Publisher Site | Google Scholar
I. Inoue, S.-I. Goto, T. Matsunaga et al., “The ligands/activators for peroxisome proliferator-activated receptor $a$ (PPAR $a$ ) and PPAR $?$ increase ${Cu}^{2 +}$ , ${Zn}^{2 +}$ -superoxide dismutase and decrease p22phox message expressions in primary endothelial cells,” Metabolism, vol. 50, no. 1, pp. 3–11, 2001.
View at: Publisher Site | Google Scholar
J. Hwang, D. J. Kleinhenz, B. Lasségue, K. K. Griendling, S. Dikalov, and C. M. Hart, “Peroxisome proliferator-activated receptor- $γ$ ligands regulate endothelial membrane superoxide production,” American Journal of Physiology, vol. 288, no. 4, pp. C899–C905, 2005.
View at: Publisher Site | Google Scholar
M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, “Effect of peroxisome proliferator-activated receptor- $α$ and - $γ$ activators on vascular remodeling in endothelin-dependent hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 45–51, 2003.
View at: Publisher Site | Google Scholar
K. Kato, H. Satoh, Y. Endo et al., “Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPAR $?$ in endothelial function,” Biochemical and Biophysical Research Communications, vol. 258, no. 2, pp. 431–435, 1999.
View at: Publisher Site | Google Scholar
R. E. Law, W. P. Meehan, X.-P. Xi et al., “Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia,” Journal of Clinical Investigation, vol. 98, no. 8, pp. 1897–1905, 1996.
View at: Google Scholar
X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor $γ$ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999.
View at: Publisher Site | Google Scholar
F. J. Schopfer, Y. Lin, P. R. S. Baker et al., “Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor $?$ ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005.
View at: Publisher Site | Google Scholar
T. Cui, F. J. Schopfer, J. Zhang et al., “Nitrated fatty acids: endogenous anti-inflammatory signaling mediators,” Journal of Biological Chemistry, vol. 281, no. 47, pp. 35686–35698, 2006.
View at: Publisher Site | Google Scholar
U. Ikeda, M. Shimpo, Y. Murakami, and K. Shimada, “Peroxisome proliferator-activated receptor- $γ$ ligands inhibit nitric oxide synthesis in vascular smooth muscle cells,” Hypertension, vol. 35, no. 6, pp. 1232–1236, 2000.
View at: Google Scholar
K. Murao, H. Imachi, A. Momoi et al., “Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells,” FEBS Letters, vol. 454, no. 1-2, pp. 27–30, 1999.
View at: Publisher Site | Google Scholar
S. M. Jackson, F. Parhami, X.-P. Xi et al., “Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 9, pp. 2094–2104, 1999.
View at: Google Scholar
H. F. Frasch, C. Marshall, and B. E. Marshall, “Endothelin-1 is elevated in monocrotaline pulmonary hypertension,” American Journal of Physiology, vol. 276, no. 2, part 1, pp. L304–L310, 1999.
View at: Google Scholar
H. Li, S.-J. Chen, Y.-F. Chen et al., “Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia,” Journal of Applied Physiology, vol. 77, no. 3, pp. 1451–1459, 1994.
View at: Google Scholar
N. L. Jernigan, B. R. Walker, and T. C. Resta, “Endothelium-derived reactive oxygen species and endothelin-1 attenuate NO-dependent pulmonary vasodilation following chronic hypoxia,” American Journal of Physiology, vol. 287, no. 4, pp. L801–L808, 2004.
View at: Publisher Site | Google Scholar
P. Delerive, F. Martin-Nizard, G. Chinetti et al., “Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway,” Circulation Research, vol. 85, no. 5, pp. 394–402, 1999.
View at: Google Scholar
F. Martin-Nizard, C. Furman, P. Delerive et al., “Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells,” Journal of Cardiovascular Pharmacology, vol. 40, no. 6, pp. 822–831, 2002.
View at: Publisher Site | Google Scholar
H. Olschewski, F. Rose, R. Schermuly et al., “Prostacyclin and its analogues in the treatment of pulmonary hypertension,” Pharmacology and Therapeutics, vol. 102, no. 2, pp. 139–153, 2004.
View at: Publisher Site | Google Scholar
M. W. Geraci, B. Gao, D. C. Shepherd et al., “Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension,” Journal of Clinical Investigation, vol. 103, no. 11, pp. 1509–1515, 1999.
View at: Google Scholar
Y. Hoshikawa, N. F. Voelkel, T. L. Gesell et al., “Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 2, pp. 314–318, 2001.
View at: Google Scholar
I. M. Robbins, J. D. Morrow, and B. W. Christman, “Oxidant stress but not thromboxane decreases with epoprostenol therapy,” Free Radical Biology and Medicine, vol. 38, no. 5, pp. 568–574, 2005.
View at: Publisher Site | Google Scholar
E. B. Rosenzweig and R. J. Barst, “Pulmonary arterial hypertension: a comprehensive review of pharmacological treatment,” Treatments in Respiratory Medicine, vol. 5, no. 2, pp. 117–127, 2006.
View at: Publisher Site | Google Scholar
D. Bishop-Bailey, “Peroxisome proliferator-activated receptors in the cardiovascular system,” British Journal of Pharmacology, vol. 129, no. 5, pp. 823–834, 2000.
View at: Publisher Site | Google Scholar
M. E. Burleigh, V. R. Babaev, J. A. Oates et al., “Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice,” Circulation, vol. 105, no. 15, pp. 1816–1823, 2002.
View at: Publisher Site | Google Scholar
R. E. Law, S. Goetze, X.-P. Xi et al., “Expression and function of PPAR $?$ in rat and human vascular smooth muscle cells,” Circulation, vol. 101, no. 11, pp. 1311–1318, 2000.
View at: Google Scholar
K. Subbaramaiah, D. T. Lin, J. C. Hart, and A. J. Dannenberg, “Peroxisome proliferator-activated receptor $γ$ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300,” Journal of Biological Chemistry, vol. 276, no. 15, pp. 12440–12448, 2001.
View at: Publisher Site | Google Scholar
J.-Y. Liou, S. Lee, D. Ghelani, N. Matijevic-Aleksic, and K. K. Wu, “Protection of endothelial survival by peroxisome proliferator-activated receptor- $δ$ mediated 14-3-3 upregulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1481–1487, 2006.
View at: Publisher Site | Google Scholar
Z. Wang, N. Jin, S. Ganguli, D. R. Swartz, L. Li, and R. A. Rhoades, “Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction,” American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 5, pp. 628–635, 2001.
View at: Google Scholar
T. Nagaoka, Y. Morio, N. Casanova et al., “Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats,” American Journal of Physiology, vol. 287, no. 4, pp. L665–L672, 2004.
View at: Publisher Site | Google Scholar
T. P. Robertson, M. Dipp, J. P. T. Ward, P. I. Aaronson, and A. M. Evans, “Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat,” British Journal of Pharmacology, vol. 131, no. 1, pp. 5–9, 2000.
View at: Publisher Site | Google Scholar
K. A. Fagan, M. Oka, N. R. Bauer et al., “Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase,” American Journal of Physiology, vol. 287, no. 4, pp. L656–L664, 2004.
View at: Publisher Site | Google Scholar
K. Abe, H. Shimokawa, K. Morikawa et al., “Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats,” Circulation Research, vol. 94, no. 3, pp. 385–393, 2004.
View at: Publisher Site | Google Scholar
T. Nagaoka, K. A. Fagan, S. A. Gebb et al., “Inhaled Rho-kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 5, pp. 494–499, 2005.
View at: Publisher Site | Google Scholar
J.-M. Hyvelin, K. Howell, A. Nichol, C. M. Costello, R. J. Preston, and P. McLoughlin, “Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation,” Circulation Research, vol. 97, no. 2, pp. 185–191, 2005.
View at: Publisher Site | Google Scholar
S. Wakino, K. Hayashi, T. Kanda et al., “Peroxisome proliferator-activated receptor $?$ ligands inhibit Rho/Rho-kinase pathway by inducing protein tyrosine phosphatase SHP-2,” Circulation Research, vol. 95, no. 5, pp. e45–e55, 2004.
View at: Publisher Site | Google Scholar
Y. Chang, B. Ceacareanu, M. Dixit, N. Sreejayan, and A. Hassid, “Nitric oxide-induced motility in aortic smooth muscle cells: role of protein tyrosine phosphatase SHP-2 and GTP-binding protein Rho,” Circulation Research, vol. 91, no. 5, pp. 390–397, 2002.
View at: Publisher Site | Google Scholar
Z. Chen, S. Ishibashi, S. Perrey et al., “Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 372–377, 2001.
View at: Google Scholar
A. R. Collins, W. P. Meehan, U. Kintscher et al., “Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 365–371, 2001.
View at: Google Scholar
A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass, “Peroxisome proliferator-activated receptor $γ$ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 523–531, 2000.
View at: Google Scholar
S. Goetze, A. Bungenstock, C. Czupalla et al., “Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR $?$ -ligands,” Hypertension, vol. 40, no. 5, pp. 748–754, 2002.
View at: Publisher Site | Google Scholar
C. M. Halabi and C. D. Sigmund, “Peroxisome proliferator-activated receptor- $γ$ and its agonists in hypertension and atherosclerosis: mechanisms and clinical implications,” American Journal of Cardiovascular Drugs, vol. 5, no. 6, pp. 389–398, 2005.
View at: Publisher Site | Google Scholar
R. Avena, M. E. Mitchell, E. S. Nylen, K. M. Curry, and A. N. Sidawy, “Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes,” Journal of Vascular Surgery, vol. 28, no. 6, pp. 1024–1032, 1998, discussion 1031–1032.
View at: Publisher Site | Google Scholar
L. Cominacini, U. Garbin, A. Fratta Pasini et al., “Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients,” Diabetes, vol. 47, no. 1, pp. 130–133, 1998.
View at: Publisher Site | Google Scholar
T. Murakami, S. Mizuno, K. Ohsato et al., “Effects of troglitazone on frequency of coronary vasospastic-lnduced angina pectoris in patients with diabetes mellitus,” American Journal of Cardiology, vol. 84, no. 1, pp. 92–94, 1999.
View at: Publisher Site | Google Scholar
A. B. Walker, P. D. Chattington, R. E. Buckingham, and G. Williams, “The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats,” Diabetes, vol. 48, no. 7, pp. 1448–1453, 1999.
View at: Publisher Site | Google Scholar
Q. N. Diep, M. El Mabrouk, J. S. Cohn et al., “Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor- $?$ ,” Circulation, vol. 105, no. 19, pp. 2296–2302, 2002.
View at: Publisher Site | Google Scholar
K. Takeda, T. Ichiki, T. Tokunou et al., “Peroxisome proliferator-activated receptor $?$ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells,” Circulation, vol. 102, no. 15, pp. 1834–1839, 2000.
View at: Google Scholar
J. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama, “Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 5, pp. 1818–1820, 1998.
View at: Publisher Site | Google Scholar
T. Takagi, T. Akasaka, A. Yamamuro et al., “Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study,” Journal of the American College of Cardiology, vol. 36, no. 5, pp. 1529–1535, 2000.
View at: Publisher Site | Google Scholar
J. S. Sidhu, Z. Kaposzta, H. S. Markus, and J. C. Kaski, “Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 930–934, 2004.
View at: Publisher Site | Google Scholar
J. Hetzel, B. Balletshofer, K. Rittig et al., “Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1804–1809, 2005.
View at: Publisher Site | Google Scholar
U. Campia, L. A. Matuskey, and J. A. Panza, “Peroxisome proliferator-activated receptor- $γ$ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors,” Circulation, vol. 113, no. 6, pp. 867–875, 2006.
View at: Publisher Site | Google Scholar
S. Ameshima, H. Golpon, C. D. Cool et al., “Peroxisome proliferator-activated receptor gamma (PPAR $?$ ) expression is decreased in pulmonary hypertension and affects endothelial cell growth,” Circulation Research, vol. 92, no. 10, pp. 1162–1169, 2003.
View at: Publisher Site | Google Scholar
D. Bishop-Bailey and T. Hla, “Endothelial cell apoptosis induced by the peroxisome proliferator- activated receptor (PPAR) ligand 15-deoxy- $Δ^{12, 14}$ -prostaglandin $J_{2}$ ,” Journal of Biological Chemistry, vol. 274, no. 24, pp. 17042–17048, 1999.
View at: Publisher Site | Google Scholar
M. B. Dancu, D. E. Berardi, J. P. Vanden Heuvel, and J. M. Tarbell, “Asynchronous shear stress and circumferential strain reduces endothelial NO synthase and cyclooxygenase-2 but induces endothelin-1 gene expression in endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2088–2094, 2004.
View at: Publisher Site | Google Scholar
J. Hwang, A. Saha, Y. C. Boo et al., “Oscillatory shear stress stimulates endothelial production of $O_{2}^{-}$ from ${p47}^{p h o x}$ -dependent NAD(P)H oxidases, leading to monocyte adhesion,” Journal of Biological Chemistry, vol. 278, no. 47, pp. 47291–47298, 2003.
View at: Publisher Site | Google Scholar
J. S. McNally, M. E. Davis, D. P. Giddens et al., “Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress,” American Journal of Physiology, vol. 285, no. 6, pp. H2290–H2297, 2003.
View at: Google Scholar
Y. Matsuda, Y. Hoshikawa, S. Ameshima et al., “Effects of peroxisome proliferator-activated receptor $?$ ligands on monocrotaline-induced pulmonary hypertension in rats,” Nihon Kokyuki Gakkai Zasshi, vol. 43, no. 5, pp. 283–288, 2005.
View at: Google Scholar
Y. Lin, X. Zhu, F. L. McIntee et al., “Interferon regulatory factor-1 mediates PPAR $γ$ -induced apoptosis in vascular smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 2, pp. 257–263, 2004.
View at: Publisher Site | Google Scholar
T. Okura, M. Nakamura, Y. Takata, S. Watanabe, Y. Kitami, and K. Hiwada, “Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 407, no. 3, pp. 227–235, 2000.
View at: Publisher Site | Google Scholar
K. R. Stenmark and I. F. McMurtry, “Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal?” Circulation Research, vol. 97, no. 2, pp. 95–98, 2005.
View at: Publisher Site | Google Scholar
J. T. Crossno Jr., K. G. Morris Jr., and D. J. Klemm, “Attenuation of hypoxia-induced pulmonary artery remodeling by a peroxisome proliferator-activated receptor- $γ$ agonist,” Chest, vol. 128, 6, p. 580S, 2005.
View at: Publisher Site | Google Scholar
J. Hwang, D. J. Kleinhenz, H. L. Rupnow et al., “The PPAR $?$ ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice,” Vascular Pharmacology, vol. 46, no. 6, pp. 456–462, 2007.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2007 Rachel E. Nisbet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

442

Downloads

788

Citations